NervGen Pharma Corp. Total Liabilities
NervGen Pharma Corp. total liabilities. Based on the latest financial reports, NervGen Pharma Corp. (NGEN) has total liabilities worth $73.03 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check NervGen Pharma Corp. liquidity resilience to evaluate the company's liquid asset resilience ratio.
Total Liabilities of NervGen Pharma Corp. (2018–2025)
Total liabilities of NervGen Pharma Corp. from 2018 to 2025. This chart illustrates how NervGen Pharma Corp.'s total liabilities have evolved over time, based on quarterly financial data. Explore how much of NervGen Pharma Corp.'s assets are long-term investments to see how much of total assets are deployed in long-term investments.
NervGen Pharma Corp. Competitors by Total Liabilities
The table below lists competitors of NervGen Pharma Corp. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
DIRECTA SIM SPA
F:ZP7
|
Germany | €76.80 Million |
|
Map Boga Adiperkasa Tbk PT
JK:MAPB
|
Indonesia | Rp1.35 Trillion |
|
TYM Corporation
KO:002900
|
Korea | ₩468.86 Billion |
|
Asia Plus Group Holdings PCL
BK:ASP
|
Thailand | ฿4.53 Billion |
|
Warehouses Estates Belgium SCA
BR:WEB
|
Belgium | €160.60 Million |
|
Beijing Chieftain Control Engineering Technology Co Ltd
SHE:300430
|
China | CN¥1.49 Billion |
|
Multitude SE
LSE:0R4W
|
UK | €1.31 Billion |
Liability Composition Analysis (2018–2025)
This chart breaks down NervGen Pharma Corp.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see NervGen Pharma Corp. asset portfolio.
Liquidity & Leverage Metrics
NervGen Pharma Corp. Total Liabilities Ratios Explained
NervGen Pharma Corp. total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.23 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 4.22 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.81 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how NervGen Pharma Corp.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for NervGen Pharma Corp. (2018–2025)
The table below shows the annual total liabilities of NervGen Pharma Corp. from 2018 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $19.73 Million | +16.77% |
| 2024-12-31 | $16.90 Million | +10.83% |
| 2023-12-31 | $15.25 Million | +47.70% |
| 2022-12-31 | $10.32 Million | +850.27% |
| 2021-12-31 | $1.09 Million | +43.54% |
| 2020-12-31 | $756.78K | -20.27% |
| 2019-12-31 | $949.14K | +63.29% |
| 2018-12-31 | $581.26K | -- |
About NervGen Pharma Corp.
NervGen Pharma Corp., a biotechnology company, engages in the discovery, development, and commercialization of pharmaceutical treatments to promote nervous system repair in settings of neurotrauma and neurologic disease. The company's lead product candidate is NVG-291 that is in Phase 1b/2a clinical trial for the treatment of spinal cord injuries (SCI), stroke, multiple sclerosis, and Alzheimer's… Read more